Lupin buys anti-cholesterol drug rights for $39 mn
September 29th, 2009 - 11:30 am ICT by IANSMumbai, Sep 29 (IANS) Indian pharmaceuticals major Lupin Tuesday said it had acquired the rights for Antara, a drug to treat high blood cholesterol and high triglycerides, for $38.61 million from the US-based Oscient Pharmaceuticals.
The rights for the drug, along with related assets and inventories, have been acquired under the procedures of the US Bankruptcy Court, the company said in a regulatory filing with the Bombay Stock Exchange (BSE).
The market for similar fenofibrate drugs was $1.9 billion over the past 12 months, out of which Antara had recorded sales worth $70 million, the Lupin statement said.
“Since Antara is a previously approved, commercial product, our sales and marketing efforts will commence immediately,” said Vinita Gupta, group president and chief financial officer for Lupin.
The company had previously filed its own application for fenofibirte capsules but had sold the same to another Indian pharmaceuticals major, Dr. Reddy’s Laboratories, on Sep 21, the company said.
Lupin had registered a consolidated revenue of Rs.3,914.5 crore ($783 million) in 2008-09, while its profit after tax stood at Rs.501.5 crore ($100 million).
- Ranbaxy's full-year net profit zooms 405 percent - Feb 22, 2011
- Ranbaxy reports Rs.464.6 crore net loss - Nov 09, 2011
- Dairy giant buys Indian pharmaceutical firm - Aug 31, 2011
- Orchid Pharma to invest Rs.200 crore in niche segment - Nov 04, 2010
- Indian drug major Sun Pharma takes control of Israeli Taro - Sep 22, 2010
- Ranbaxy's June quarter net profit falls by 25 pc - Aug 05, 2011
- Ranbaxy posts $210 mn net profit - May 11, 2010
- Cash-rich Piramal picks up another 5.5 percent in Vodafone - Feb 04, 2012
- Lanco Infratech net profit plunges 2.72 percent during FY2010 - May 30, 2011
- Over 1,500 swine flu deaths in India, says Azad - May 04, 2010
- Dr Reddy's launches anti-asthma tablets in US - Nov 20, 2010
- Abbott to buy Piramal's branded drugs business for $3.71 bn (Roundup) - May 21, 2010
- NTPC's first quarter net profit up 12.69 percent - Jul 25, 2011
- Abbott to buy Piramal's branded drugs business for $3.71 bn (Lead) - May 21, 2010
- Surya Pharma's arm acquires US's ActivOn for $22 mn - Dec 28, 2010
Tags: 100 million, antara, bombay stock exchange, chief financial officer, cholesterol, cholesterol drug, consolidated revenue, dr reddy, fenofibrate, group president, gupta, high blood cholesterol, high triglycerides, indian pharmaceuticals, inventories, marketing efforts, sales and marketing, triglycerides, us bankruptcy court, vinita